FTSE 100 news / Companies and sectors / GSK / GSK Ris-Rez shows 61% response rate in lung cancer trial
GSK Ris-Rez shows 61% response rate in lung cancer trial
+7.5 strongly positive
Reports cover Ris-Rez early lung cancer data, with Jefferies backing GSK afterwards.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| Proactive financial news | 2 | +9.8 |
| TradingView | 2 | +9.4 |
| Pluang | 1 | +9.2 |
| Simply Wall Street | 1 | +7.5 |
| Sharecast | 1 | +7.5 |
| pharmaphorum | 1 | +7.5 |
| MarketScreener | 1 | +7.5 |
| Stock Titan | 1 | +6.7 |
| Yahoo Finance | 1 | +5.8 |
| James Sharp & Co. | 1 | +4.2 |
| Endpoints News | 1 | +3.3 |
Day by day
Tuesday 20 October 2026
Reports cover Ris-Rez early lung cancer data, with Jefferies backing GSK afterwards.
- +9.2 Jefferies backs GSK with 2,500p target after positive lung cancer drug results
Jefferies backs GSK with high target after lung data. - +9.2 Jefferies upgrades GSK with 34% upside after st...
Jefferies upgrade with significant upside. - +7.5 What Do GSK (LSE:GSK) Oncology Wins Mean For Its Long Term Growth?
Oncology wins framed positively for long-term growth. - +7.5 GSK's Ris‑Rez shows 61pc response rate in early lung cancer study
61pc response rate in early lung cancer study. - +7.5 Data reveal is promising for GSK's lung cancer drug ris-rez
Promising data for lung cancer drug. - +7.5 GSK plc : Jefferies reiterates its Buy rating
Jefferies reiterates Buy rating. - +6.7 A 50-patient lung cancer analysis helps GSK (GSK) select a dose for its late-stage trial.
Lung cancer analysis helps select late-stage dose. - +5.8 What Is GSK (LSE:GSK) Telling Investors With Its New Lung Cancer Data?
New lung cancer data discussed for investors. - +4.2 GSK Announces Ris-Rez Update October 19, 2026
Ris-Rez update announced. - +3.3 ESMO first look: Zai Lab, GSK, Merck and others detail wins, setbacks
Mixed wins and setbacks across several companies at ESMO.
Monday 19 October 2026
Phase IB data reported.
- +10.0 GSK lung cancer drug shows 61% response rate in early global trial
Strong 61% response rate in early lung cancer trial. - +9.7 GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial
Reports 61% overall response rate in Phase IB trial. - +9.2 REG - GSK PLC - Ris-Rez positive early data in lung cancer
Company announcement of positive early lung cancer data.